Skip to main content

Table 3 Adverse effects in patients with LCH treated with MA regimen

From: The combination of methotrexate and cytosine arabinoside in newly diagnosed adult Langerhans cell histiocytosis: a prospective phase II interventional clinical trial

Adverse Effects No. (%)
Hematological toxicity
 Neutropenia 29 (80.6%)
  Grade 2 1 (2.8%)
  Grade 3 5 (13.9%)
  Grade 4 23 (63.9%)
 Thrombocytopenia 15 (41.7%)
  Grade 1 1 (2.8%)
  Grade 2 2 (5.6%)
  Grade 3 5 (13.9%)
  Grade 4 7 (19.4%)
Non-hematological toxicity
 Allergic reaction 8 (22.2%)
  Grade 1 1 (2.8%)
  Grade 2 7 (19.4%)
 Liver function abnormality 3 (8.3%)
  Grade 2 3 (8.3%)
 Nausea 5 (13.9%)
  Grade 1 1 (2.8%)
  Grade 2 4 (11.1%)
 Vomit 3 (8.3%)
  Grade 1 2 (5.6%)
  Grade 2 1 (2.8%)
 Diarrhea 3 (8.3%)
  Grade 1 3 (8.3%)
 Infection event 4 (11.1%)
  Grade 2 2 (1 case of gingival, and 1 case of skin)
  Grade 3 2 (1 case of lung, and 1 case of digestive tract)
  1. No death from chemotherapy observed